NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

ex,

Thanks for posting your pearls of wisdom 😶

The landmark P3 was pivotal, exemplary, ethical, compassionate, and clinically appropriate. Along with data from the Specials Program, it represents a core, foundational, and extensive data set supporting both the safety and efficacy of the cell-based platform… but a new day is dawning, we have bigger fish to fry, and we are moving forward…

⭐️Firstly, in addition to DCVax-L and DCVax-D, NWBO now owns another patent-fortified novel DC platform technology developed by Roswell Park in New York…

⭐️Secondly, in case you haven’t noticed, we are entering an exciting new era of COMBINATION therapies!

Immuno-oncology is evolving and there is a shifting new reality coming into focus for BP’s most profitable drugs: It’s quite possible that large pharma companies that have built their oncology portfolios around checkpoint inhibitors will eventually need to integrate dendritic cell-based strategies to stay competitive. If they don’t, smaller biotechs and research-driven companies will take the lead, forcing larger players to follow or risk being left behind.

There are developments taking shape on this front—for example: Ampligen® (rintatolimod) seems to be emerging as a possible key agent for new combos with PD-1 drugs and DC vaccine platforms.

The company called AIM ImmunoTech has been the recipient of peer-reviewed grants awarded by the U.S. DoD and NCI for new combo research!



https://aimimmuno.com/




https://www.sec.gov/Archives/edgar/data/946644/000149315219014466/ex99-1.htm

https://clinicaltrials.gov/study/NCT04093323?a=39

https://clinicaltrials.gov/study/NCT02432378?tab=table&a=22

Roswell Park has a strong interest in Ampligen as a combination therapy agent. While Oncovir’s Hiltonol may play a significant role for UCLA and DCVax-L, AIM ImmunoTech’s Ampligen could be a key player in Roswell Park’s combination research, as clinical studies work to piece together effective combination therapies.

There are some interesting connections between Roswell Park and Moffitt, particularly in their dendritic cell research and studies involving new applications for rintatolimod.

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html

https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/